Timed release masking particles and oral pharmaceutical compositions containing same
Masking particles with a water-insoluble polymer coating control drug release in the oral cavity and pharynx, masking taste and preventing unwanted absorption, while ensuring rapid release in the stomach and intestines for effective drug delivery.
Patent Information
- Application Number
- JP2021528149
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-17
- Filing Date
- 2020-06-10
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-06-10
AI Technical Summary
Existing oral pharmaceutical preparations, such as tablets and granules, struggle with rapid drug release in the oral cavity, leading to unpleasant taste and potential side effects, and lack the ability to control drug release suppression time effectively.
Masking particles coated with a water-insoluble polymer layer containing a drug, acid, and carbonate, which suppress drug release in the oral cavity and pharynx until swallowed, allowing rapid drug release in the stomach and intestines by reacting with water to foam and break the coating.
The masking particles effectively mask the unpleasant taste of drugs, prevent unwanted absorption in the oral cavity, and allow controlled drug release in the gastrointestinal tract, ensuring effective drug absorption and efficacy.
Smart Images

Figure 0007584413000011 
Figure 0007584413000012 
Figure 0007584413000013
Abstract
Description
[Technical field]
[0001] The present invention relates to a masking particle that can suppress the release of a drug in the oral cavity or pharynx and control the release of the drug without hindering the release of the drug in the stomach or intestines, and an oral pharmaceutical composition containing the same. More specifically, the present invention relates to a masking particle that reduces the taste of the drug when taken, particularly the taste of a drug having an unpleasant taste, and an oral pharmaceutical composition containing the same. [Background technology]
[0002] Tablets and capsules are widely used as oral pharmaceutical preparations, but they are difficult to swallow for elderly people and children who have low swallowing ability. For this reason, orally disintegrating tablets that disintegrate quickly in the oral cavity are attracting attention because they are easy to swallow and can be taken without water. However, since orally disintegrating tablets disintegrate in the oral cavity, when they contain drugs with unpleasant tastes such as bitterness, they have the disadvantage of strongly feeling the unpleasant taste. In addition, granules, fine granules, powders, etc. are smaller in size than tablets and capsules, so they are dosage forms that are easy to swallow. However, these preparations have a large surface area per weight, so when they contain drugs with unpleasant tastes, they have the disadvantage of strongly feeling the unpleasant taste. In addition, orally disintegrating tablets, granules, fine granules, powders, and the like rapidly release drugs when they come into contact with moisture in the oral cavity, and some drugs may be absorbed through the oral cavity or pharynx, causing a rapid increase in blood concentration, resulting in unexpected side effects and inconsistent efficacy.
[0003] In order to mask the unpleasant taste of medicinal ingredients felt when taking them or to suppress absorption of the medicinal ingredients from the oral cavity or pharynx, granules, fine granules, powders, tablets, etc. have been coated with a coating agent containing a water-insoluble polymer. When an oral pharmaceutical preparation is coated, the taste of the medicinal ingredients is not felt in the mouth and the medicinal ingredients are not absorbed from the oral cavity or pharynx, but the release of the drug is delayed, so that a sufficient amount of the drug is not absorbed, and the desired medicinal effect may not be obtained. Drugs are usually absorbed from the stomach or intestines, and since the upper small intestine has a larger surface area involved in absorption than the lower small intestine or the large intestine, and the permeability of the intercellular space is also considered to be high, it is believed that drugs absorbed from the intestine are mainly absorbed from the upper small intestine. Therefore, oral pharmaceutical preparations are required to suppress the release of drugs in the oral cavity and to release the drugs before the preparation reaches the stomach or the upper small intestine or while it is retained therein. In particular, drugs that act on the stomach or intestines, such as gastric mucosa protective drugs, antacids, digestive drugs, intestinal regulators, anthelmintics, gastrointestinal analgesics and antispasmodics, need to be released before the preparation reaches the stomach or the upper small intestine or while it is retained therein. In addition, since the degree of unpleasant taste and absorption pattern differ depending on the type of drug, and the oral residence time differs depending on the dosage form of the preparation, it is desirable to be able to arbitrarily control the drug release inhibition time.
[0004] As an oral pharmaceutical composition in which the release of a drug in the oral cavity is suppressed, Patent Document 1 discloses a particulate pharmaceutical composition having a core particle containing a drug having an unpleasant taste in the center, a layer containing two types of water-soluble components, an insolubilizer and an insolubilizing substance, in an intermediate layer, and a water penetration control layer in the outermost layer, in which the intermediate layer contains a salting-out type insolubilizer and a salting-out insolubilizing substance, or an acid type insolubilizer and an acid insolubilizing substance. According to Patent Document 1, this particulate composition does not allow water to penetrate for a certain period of time due to the presence of the water penetration control layer, and the insolubilizer promotes the insolubilization of the insolubilizing substance to suppress the dissolution of the drug, but after that, the insolubilizer is released by the penetration of water, causing the insolubilizing substance to regain its original water solubility, and the drug is released. However, with the particulate pharmaceutical composition of Patent Document 1, it is difficult to arbitrarily control the drug release inhibition time, and the dissolution of the drug is particularly slow. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] Patent No. 4277904 Summary of the Invention [Problem to be solved by the invention]
[0006] An object of the present invention is to provide masking particles in which drug release in the oral cavity and pharynx is sufficiently suppressed and the drug is rapidly released after swallowing, and further the drug release suppression time is easily controlled, and an oral pharmaceutical composition containing the same. [Means for solving the problem]
[0007] The present inventors have conducted extensive research to solve the above problems, and have found that masked particles, in which particles containing a drug, an acid, and a carbonate are covered with a coating layer containing a water-insoluble polymer, inhibit the dissolution of the drug in the mouth and pharynx due to the presence of the coating layer, but that thereafter, moisture gradually penetrates into the inside through the coating layer, and the masked particles are destroyed by foaming caused by a reaction between the acid and the carbonate, resulting in the rapid release of the drug.
[0008] The present invention has been completed based on the above findings, and provides the following [1] to
[22] . [1] A masked particle in which a drug-containing particle containing a drug, an acid, and a carbonate is coated with a coating layer containing a water-insoluble polymer. [2] The masked particle according to [1], wherein the acid is one or more organic acids. [3] The masked particle according to [1] or [2], wherein the carbonate is one or more water-soluble carbonates. [4] The masked particle according to any one of [1] to [3], which contains an acid in an amount of 0.5 to 30% by weight based on the total amount of the drug-containing particle. [5] The masked particle according to any one of [1] to [4], which contains 0.5 to 35% by weight of carbonate based on the total amount of the drug-containing particle. [6] The masking particles according to any one of [1] to [5], which contain 0.1 to 10 parts by weight of a carbonate relative to 1 part by weight of the acid. [7] The masked particle according to any one of [1] to [6], wherein the content of the coating layer is 0.005 to 2 parts by weight per 1 part by weight of the drug-containing particle. [8] The masked particle according to any one of [1] to [7], wherein the drug-containing particle is a uniform particle containing a drug, an acid, and a carbonate. [9] The masked particle according to any one of [1] to [7], wherein the drug-containing particle has a portion containing a drug and a portion containing an acid and a carbonate separately.
[10] The masked particle according to [9], wherein the drug-containing particle comprises a core particle and an intermediate layer covering it, and the drug is contained in the core particle and the acid and carbonate are contained in the intermediate layer, or the acid and carbonate are contained in the core particle and the drug is contained in the intermediate layer.
[11] The masked particle according to
[10] , wherein the core particle contains a disintegrant.
[12] The masked particle according to
[10] or
[11] , wherein the intermediate layer contains a binder and / or a flow agent or a lubricant.
[13] The masked particle according to any one of [1] to [7], wherein the drug-containing particle has a portion containing an acid and a portion containing a carbonate separately.
[14] The masked particle according to
[13] , wherein the drug-containing particle comprises a core particle and an intermediate layer covering the core particle, the acid and the carbonate are contained separately in either the core particle or the intermediate layer, and the drug is contained in the core particle, the intermediate layer, or both.
[15] The masked particle according to
[14] , wherein the core particle contains a disintegrant.
[16] The masked particle according to
[14] or
[15] , wherein the intermediate layer contains a binder and / or a flow agent or a lubricant.
[17] The masked particle according to
[13] , wherein the drug-containing particle comprises a core particle and first and second intermediate layers, and the drug, acid, and carbonate are separately contained in either the core particle, the first intermediate layer, or the second intermediate layer.
[18] The masked particle according to
[17] , wherein the core particle contains a disintegrant.
[19] The masked particle according to
[17] or
[18] , wherein either or both of the first and second intermediate layers contain a binder and / or a flow agent or lubricant.
[20] A tablet, granule, fine granule, or powder comprising the masked particle according to any one of [1] to
[19] .
[21] An orally disintegrating tablet comprising the masked particle according to any one of [1] to
[19] .
[22] A method for controlling the dissolution or release of a drug from a drug-containing particle, by adding an acid and a carbonate to the drug-containing particle and coating the drug-containing particle containing a drug, an acid, and a carbonate with a coating layer containing a water-insoluble polymer. Effect of the Invention
[0009] The masked particles of the present invention are particles containing a drug, and are coated with a coating layer containing a water-insoluble polymer, so that the taste of the drug is not felt in the mouth or the taste of the drug is reduced, and therefore the masked particles can be suitably used for the production of pharmaceutical compositions containing drugs having unpleasant tastes such as bitterness. In addition, the masked particles of the present invention can be suitably used as granules, fine granules, or powders, which are generally dosage forms that make the taste of the drug easily felt in the mouth, and these preparations make it difficult or impossible to feel the taste of the drug in the mouth. Furthermore, the masked particles of the present invention can be used for the manufacture of tablets. Even if the tablet manufactured using the masked particles of the present invention is an orally disintegrating tablet, the taste of the drug is not felt or is difficult to feel in the mouth because the particles containing the drug are coated. If a tablet is coated to suppress the taste of the drug, it generally does not become an orally disintegrating tablet, but if the masked particles of the present invention are used, an orally disintegrating tablet with suppressed taste of the drug can be manufactured.
[0010] In addition, since the masked particles of the present invention are drug-containing particles coated with a coating layer containing a water-insoluble polymer, the release of the drug due to contact with water in the oral cavity is suppressed, and therefore the absorption of the drug from the oral cavity and pharynx is suppressed, thereby avoiding the occurrence of unexpected side effects due to the absorption of the drug from the oral cavity and pharynx and the variation in efficacy between individuals. Furthermore, the masked particles of the present invention are suitable for use in the production of gastric and enteric preparations, since the absorption of drugs from the oral cavity and pharynx is suppressed.
[0011] After being swallowed, the masked particles of the present invention are gradually permeated by moisture in the digestive tract through the coating layer, and moisture penetrates the inside, whereupon the acid and carbonate react quickly to form foam, destroying the masked particles and releasing the drug. Therefore, the drug can be sufficiently absorbed from the stomach and intestines (especially the upper part of the small intestine). In addition, drugs targeted to the stomach and intestines can also be sufficiently effective.
[0012] The masked particles of the present invention can release a drug at a desired time by adjusting the type of water-insoluble polymer, the thickness of the coating layer, the type and amount of the acid and carbonate, the type and amount of other components, the layer structure of the drug-containing particles, etc. Therefore, the drug release inhibition time can be arbitrarily controlled depending on the type and dosage form of the drug. In addition, since the acid and carbonate react rapidly in the presence of water to generate foam, the masked particles of the present invention allow for accurate control of the drug release inhibition time, making it possible to prepare a formulation with a desired drug release pattern according to the drug and dosage form. [Brief description of the drawings]
[0013] [Figure 1] FIG. 13 shows the results of a drug elution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer. [Diagram 2] FIG. 1 is a graph comparing drug dissolution between drug-containing particles containing acid and those not containing acid. [Diagram 3] This figure shows the results of a drug dissolution test for a masked particle comprising a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, in which the type of water-insoluble polymer in the coating layer is different from that of the masked particle in Figure 1. [Figure 4] FIG. 2 shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate contents of which are less than those of the masked particle in FIG. 1. [Diagram 5]FIG. 5 shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate contents of which are less than those of the masked particle in FIG. [Figure 6] This figure shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, in which the type of binder in the intermediate layer is different from that of the masked particle in Figure 1. [Figure 7] FIG. 13 shows the results of a drug elution test for a masked particle having a core particle containing a drug and a carbonate, an intermediate layer containing an acid, and a coating layer. [Figure 8] FIG. 2 shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the disintegrant content in the core particle being different from that of the masked particle in FIG. 1. [Figure 9] This figure shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate content ratio of which is different from that of the masked particle in Figure 1. [Figure 10] This figure shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate content ratio of which is different from that of the masked particle in Figure 1. [Figure 11] This figure shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate content ratio of which is different from that of the masked particle in Figure 4. [Figure 12] This figure shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate content ratio of which is different from that of the masked particle in Figure 4. [Figure 13] This figure shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate content ratio of which is different from that of the masked particle in Figure 5. [Figure 14] This figure shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, the acid and carbonate content ratio of which is different from that of the masked particle in Figure 5. [Figure 15] FIG. 2 shows the results of a drug elution test for a masked particle having a core particle containing a drug, a first intermediate layer containing an acid, a second intermediate layer containing a carbonate, and a coating layer. [Figure 16] This figure shows the results of a drug dissolution test for a masked particle comprising a core particle coated with a drug, a first intermediate layer consisting of an excipient, a second intermediate layer containing an acid, a third intermediate layer containing a carbonate, and a coating layer. [Figure 17] FIG. 1 shows the results of a drug dissolution test for a masked particle having a core particle containing a drug and an acid, an intermediate layer containing a carbonate, and a coating layer, as well as an orally disintegrating tablet produced using the same. [Figure 18] This figure shows the results of a drug dissolution test for a masked particle comprising a core particle coated with a drug, a first intermediate layer made of an excipient, a second intermediate layer containing an acid, a third intermediate layer containing a carbonate, and a coating layer, where the type of acid is different from that of the masked particle in Figure 16. [Figure 19] This figure shows the results of a drug dissolution test for a masked particle comprising a core particle coated with a drug, a first intermediate layer containing an acid, a second intermediate layer made of an excipient, a third intermediate layer containing a carbonate, and a coating layer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The present invention will be described in detail below. The masked particle of the present invention is a particle containing a drug, an acid, and a carbonate, and coated with a coating layer containing a water-insoluble polymer. The masked particle of the present invention can be made into tablets, granules, fine granules, powders, etc., either alone or in combination with an additive. In the present invention, the granular portion containing the drug, acid, and carbonate is called a "drug-containing particle," and the "drug-containing particle" coated with a coating layer containing a water-insoluble polymer is called a "masked particle." As described below, the granular portion containing the drug, acid, and carbonate (excluding the coating layer) may be a particle of a single composition or may consist of a central core and an intermediate layer surrounding it, but in either case, the portion excluding the coating layer is called a "drug-containing particle."
[0015] acid The acid is not particularly limited as long as it is an acidic substance that generates carbonic acid by reacting with a carbonate, and includes pharmaceutical acceptable acidic additives and active pharmaceutical ingredients. Usually, an acidic substance having a pKa value smaller than that of carbonic acid can be used, and organic acids, inorganic acids, or salts thereof are preferred. Examples of organic acids include carboxylic acids such as acetic acid, fumaric acid, maleic acid, succinic acid, malonic acid, lactic acid, tartaric acid, citric acid, malic acid, ascorbic acid (vinyl carboxylic acid), glycolic acid, adipic acid, and carboxymethylcellulose; sulfonic acids such as toluenesulfonic acid; amino acids; and glucono delta lactone. Examples of organic acid salts include potassium tartrate. Examples of inorganic acids include hydrochloric acid, nitric acid, sulfuric acid, and phosphoric acid. Examples of inorganic acid salts include calcium monophosphate. Among them, organic acids are preferred, carboxylic acids are more preferred, citric acid, tartaric acid, and malic acid are even more preferred, and citric acid is particularly preferred. The acid may be in the form of a hydrate. The acids can be used alone or in combination of two or more.
[0016] The content of the acid is preferably 1% by weight or more, more preferably 3% by weight or more, and even more preferably 5% by weight or more, based on the total amount of the drug-containing particles. Also, it is preferably 35% by weight or less, more preferably 25% by weight or less, and even more preferably 20% by weight or less. Within this range, the masking particles can be quickly destroyed by reaction with carbonate in the stomach or intestines, and the drug can be released.
[0017] Carbonate The carbonate may be any pharma- ceutically acceptable carbonate, and examples of water-soluble carbonates include sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, ammonium carbonate, etc. Examples of water-insoluble or poorly water-soluble carbonates include calcium carbonate, magnesium carbonate, etc. Among these, water-soluble carbonates are preferred, bicarbonates are more preferred, and sodium bicarbonate and potassium bicarbonate are even more preferred. The carbonates can be used alone or in combination of two or more.
[0018] The content of carbonate is preferably 0.1% by weight or more, more preferably 3% by weight or more, and even more preferably 5% by weight or more, based on the total amount of the drug-containing particles. Also, it is preferably 35% by weight or less, more preferably 25% by weight or less, and even more preferably 20% by weight or less. Within this range, the masking particles can be quickly destroyed by reaction with the acid, and the drug can be released.
[0019] The ratio of the content of the acid to the carbonate is preferably 0.1 parts by weight or more of the carbonate per 1 part by weight of the acid, more preferably 0.3 parts by weight or more, and even more preferably 0.5 parts by weight or more. Also, it is preferably 10 parts by weight or less, more preferably 3 parts by weight or less, and even more preferably 1.5 parts by weight or less. Within this range, sufficient effervescence can be generated to achieve the desired drug dissolution.
[0020] Drugs The drug is not particularly limited. Among them, drugs that have an unpleasant taste such as bitter, sour, or irritating taste, drugs that irritate the pharynx, and drugs that are absorbed through the oral cavity or pharynx can be preferably used. Examples of drugs include antihyperlipidemic drugs (atorvastatin, pravastatin, simvastatin, rosuvastatin, etc.), quinolone antibacterial agents (moxifloxacin, gatifloxacin, sparfloxacin, tosufloxacin, sitafloxacin, levofloxacin, lomefloxacin, ciprofloxacin, fleroxacin, garenoxacin, etc.), macrolide antibiotics (clarithromycin, azithromycin, roxithromycin, erythromycin, etc.), nonsteroidal anti-inflammatory drugs (aspirin, mefenamic acid, ibuprofen, naproxen, etc.), , loxoprofen, celecoxib, etc.), high blood pressure medications (amlodipine, nifedipine, azilsartan, olmesartan medoxomil, irbesartan, losartan, candesartan cilexetil, telmisartan, etc.), diabetes medications (metformin, miglitol, voglibose, nateglinide, mitiglinide, pioglitazone, sitagliptin, vildagliptin, alogliptin, linagliptin, anagliptin, saxagliptin, teneligliptin, ipragliflozin, dapagliflozin, canagliflozin, empagliflozin, etc.), vasodilators (limaprost, beraprost, sildenafil, bosenilone, hepronicate, kallidinogenase, isoxsuprine, etc.), antidepressants (escitalopram, duloxetine, paroxetine, etc.), antipsychotics (olanzapine, quetiapine, clozapine, aripiprazole, risperidone, blonanserin, perospirone, etc.), antianxiety drugs (clotiazepam, lorazepam, diazepam, etc.), Alzheimer's disease drugs (donepezil, galantamine, rivastigmine, memantine, etc.), antiepileptic drugs (levetiracetam, galanthamine, ribastigmine ... bapentin, lamotrigine, zonisamide, carbamazepine, phenytoin, valproic acid, etc.), neuropathic pain medications (pregabalin, mirogabalin, etc.), dopamine agonists (gabergoline, pramipexole, ropinirole, bromocriptine, percolide, amantadine, etc.), antihistamines (levocetirizine, cetirizine, epinastine, olopatadine, loratadine, desloratadine, rupatadine, ebastine, bepotastine, gelastine, fexofenadine, ketotifen, emedastine, oxatomide, mequitazine, azelastine, etc.),Leukotriene inhibitors (montelukast, zafirlukast, pranlukast, etc.), overactive bladder treatments (solifenacin, imidafenacin, tolterodine, propiverine, flavoxate, clomipramine, imipramine, amitroptine, mirabegron, vibegron, etc.), molecular targeted cancer treatments (bortezomib, etc.), urinary dysfunction treatments associated with benign prostatic hyperplasia (silodosin, chlormadinone, tamsulosin, naftopidil, etc.) etc.), erectile dysfunction drugs (tadalafil, vardenafil, etc.), insomnia drugs (ramelteon, zolpidem, triazolam, nimetazepam, quazepam, etc.), osteoporosis drugs (risedronate sodium, alendronate, etc.), gout and hyperuricemia drugs (febuxostat, topiroxostat, allopurinol, etc.), hyperphosphatemia drugs (lanthanum carbonate, etc.), and their salts and solvates.
[0021] The content of the drug varies depending on the type of drug, but is preferably, for example, 90% by weight or less based on the total amount of the masked particles. The lower limit of the drug content varies depending on the drug, but may be, for example, about 0.00001% by weight based on the total amount of the masked particles.
[0022] additives The masked particles of the present invention may contain any additives used in tablets, granules, fine granules, powders, etc., in the drug-containing particles, as long as the effects of the present invention are not impaired. Examples of additives include excipients, disintegrants, binders, lubricants or fluidizing agents (anti-adhesive agents), colorants, flavorings, sweeteners, preservatives or antiseptics, etc. The additives may be used alone or in combination of two or more.
[0023] Examples of excipients include sugars such as lactose hydrate, sucrose, maltose, fructose, glucose, and trehalose; sugar alcohols such as mannitol (especially D-mannitol), maltitol, sorbitol, xylitol, erythritol, and lactitol; starches such as starch, pregelatinized starch, and partially pregelatinized starch; celluloses such as crystalline cellulose; dextrin; dextran; glycerin fatty acid esters; and inorganic powders such as magnesium aluminometasilicate and synthetic hydrotalcite.
[0024] Binders include povidone; celluloses such as methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose (hypromellose), and croscarmellose sodium; starch; gelatin; thickening polysaccharides such as agar, alginic acid, sodium alginate, tragacanth, xanthan gum, gum arabic, pullulan, and dextrin; polyvinyl alcohol-polyethylene glycol graft copolymers; carboxyvinyl polymers; polyethylene oxide; copolyvidone; polyoxyethylene hydrogenated castor oil; polymers containing N-isopropylacrylamide and / or derivatives having a hydrophobic group introduced at the N-position of acrylamide; polyoxyethylene-polyoxypropylene glycol; polyvinyl alcohol (including partially saponified polyvinyl alcohol); basic (meth)acrylate copolymers; and polyethylene glycol.
[0025] Disintegrants include crospovidone; celluloses such as carboxymethylcellulose (carmellose), carmellose sodium, carmellose calcium, low-substituted hydroxypropylcellulose, croscarmellose sodium, and crystalline cellulose; starches such as starch, pregelatinized starch, partially pregelatinized starch, sodium carboxymethyl starch, sodium carboxystarch, and hydroxypropyl starch; dextrin; calcium silicate; calcium citrate; and light anhydrous silicic acid.
[0026] Examples of lubricants or fluidizing agents (anti-adhesion agents) include stearic acid, stearates (magnesium stearate, calcium stearate, aluminum stearate, zinc stearate, etc.), sodium stearyl fumarate, glycerin monostearate, glycerin palmitostearate, sodium lauryl sulfate, polyethylene glycol, talc, glycerin fatty acid esters, sucrose fatty acid esters, sodium potassium tartrate, carnauba wax, L-leucine, polyethylene glycol, hardened oils, silicate compounds (light anhydrous silicic acid, magnesium aluminometasilicate, hydrated silicon dioxide, synthetic aluminum silicate, etc.), titanium oxide, etc.
[0027] Examples of coloring agents include yellow ferric oxide, ferric oxide, titanium oxide, black ferric oxide, edible tar dyes, and natural dyes (such as β-carotene and riboflavin).
[0028] Sweeteners include sucralose, mannitol, sucrose, aspartame, stevia, and acesulfame potassium.
[0029] Examples of the preservatives or antiseptics include ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, benzoic acid, and sodium benzoate.
[0030] Coating Layer The coating layer contains a water-insoluble polymer that is used as a coating agent in pharmaceutical preparations. In the present invention, the "water-insoluble polymer" includes not only those that are completely insoluble in water, but also those that are poorly soluble in water.
[0031] Examples of water-insoluble polymers include cellulose-based coating agents (methylcellulose, ethylcellulose, hydroxyethylcellulose, carboxymethylethylcellulose, sodium carboxymethylcellulose, hypromellose phthalate, hypromellose acetate succinate, cellulose acetate, cellulose acetate phthalate, etc.), vinyl-based polymers (polyvinyl acetal diethylaminoacetate, polyvinyl acetate phthalate, etc.), methacrylate polymers or methacrylic acid polymers, and polysiloxane-based coating agents (dimethylpolysiloxane, dimethylpolysiloxane-silicon dioxide mixture, etc.). Among these, methacrylate polymers or methacrylic acid polymers, and cellulose-based coating agents (particularly, ethyl cellulose) are preferred, and methacrylate polymers or methacrylic acid polymers are more preferred.
[0032] There are many types of commercially available methacrylate polymers or methacrylic acid polymers, such as Eudragit E series, Eudragit L series, Eudragit S series, Eudragit R series, Eudragit NE series, and Eudragit FS series (registered trademark) manufactured by Rehm Co., Ltd. Specific examples include aminoalkyl methacrylate copolymer E (Eudragit E100, EPO, etc.), methacrylic acid copolymer LD (Eudragit L30D-55, L100-55, etc.), methacrylic acid copolymer L (Eudragit L100, etc.), methacrylic acid copolymer S (Eudragit S100, etc.), ammonioalkyl methacrylate copolymer (Eudragit RL100, RLPO, RS100, RSPO, RL30D, RS30D, etc.), and ethyl acrylate-methyl methacrylate copolymer (Eudragit NE30D, etc.).
[0033] Water-insoluble polymers are classified into pH-independent polymers, enteric polymers, gastrosoluble polymers, etc., and any of them can be suitably used in the present invention, and may be selected so as to obtain a desired release inhibition time for each drug. As shown in the Examples section, when moisture gradually penetrates through the coating layer, the masked particles of the present invention react with the acid and carbonate to generate foam and destroy the masked particles, so that even when an enteric polymer is used, it is possible to design a formulation in which the drug is released before reaching the intestine.
[0034] The coating layer may contain additives such as plasticizers, binders, flow agents or lubricants (anti-adhesive agents), colorants, sweeteners, etc., within the scope of not impairing the effects of the present invention. The additives may be used alone or in combination of two or more.
[0035] Examples of the plasticizer include polyethylene glycol, propylene glycol, glycerin, glycerin fatty acid esters such as triacetin (glycerin triacetate), liquid paraffin, sorbitan monolaurate, monostearin, triethyl citrate, tributyl citrate, diethyl phthalate, dibutyl phthalate, diethyl sebacate, dibutyl sebacate, poloxamer, and polyoxyethylene hydrogenated castor oil. Binders, flow agents or lubricants (antiadhesive agents), colorants, and sweeteners include those exemplified as additives for drug-containing particles.
[0036] The content of the coating layer is preferably 0.01 parts by weight or more, more preferably 0.05 parts by weight or more, and even more preferably 0.1 parts by weight or more, relative to 1 part by weight of the drug-containing particle. Also, it is preferably 1 part by weight or less, more preferably 0.5 parts by weight or less, and even more preferably 0.3 parts by weight or less. Within this range, the water penetration speed becomes appropriate, and the release of the drug in the oral cavity and pharynx can be sufficiently suppressed, and the drug can be released quickly thereafter.
[0037] particle structure The masked particles of the present invention may be formed into particles of various structures as long as the drug-containing particles contain a drug, an acid, and a carbonate and are coated with a coating layer containing a water-insoluble polymer.
[0038] (First aspect) The masked particles can be, for example, uniform or single-part drug-containing particles containing a drug, an acid, and a carbonate, coated with a coating layer. Since this embodiment contains the acid and the carbonate in the same part, it can effervescent very quickly by the infiltration of water through the coating layer, and release the drug. The drug-containing particles can further contain any additives used in tablets, granules, fine granules, powders, etc.
[0039] (Second aspect) The masked particles may also be drug-containing particles that have a portion containing the drug and a portion containing an acid and a carbonate, and are covered with a coating layer.
[0040] For example, a drug-containing particle consisting of a core particle and a layer covering it (this layer is sometimes referred to as the "intermediate layer" below, as it exists between the core particle and the coating layer) can be made into a particle covered with a coating layer, in which a drug is blended into the core particle and an acid and a carbonate are blended into the intermediate layer, or an acid and a carbonate are blended into the core particle and a drug is blended into the intermediate layer. When the core particle contains a drug, the core particle may be composed of a central core containing an excipient etc. and a drug-containing layer surrounding the central core. This makes it easier to produce spherical drug-containing particles, facilitates the formation of a coating layer, and allows drug-containing particles with a narrow particle size distribution to be obtained. In addition, another intermediate layer made of an excipient or the like can be provided between the core particle and the intermediate layer. In this embodiment, since the acid, carbonate, and drug are mixed in separate portions, it is easy to use drugs that are sensitive to acids or alkalis. Also, since the acid and carbonate are contained in the same portion, the product foams very quickly when water penetrates through the coating layer, and the drug can be released.
[0041] In this embodiment, the core particles and the intermediate layer may further contain any additives used in granules, fine granules, powders, and the like. Among them, if the core particles contain a disintegrant, the disintegrant's water absorption property attracts water, which makes the reaction between the acid and the carbonate more likely to occur. As the disintegrant, crospovidone; celluloses such as carboxymethylcellulose (carmellose), carmellose sodium, carmellose calcium, low-substituted hydroxypropylcellulose, and crystalline cellulose are preferred, and low-substituted hydroxypropylcellulose is more preferred. The content of the disintegrant is preferably about 0.5 to 50% by weight based on the total amount of the drug-containing particles. The intermediate layer preferably contains a binder to facilitate layer formation. Preferred binders are hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose), and polyethylene glycol. The content of the binder is preferably about 0.1 to 20% by weight based on the total weight of the drug-containing particles. In addition, the intermediate layer preferably contains a fluidizer or lubricant (antiadhesive agent) to suppress electrostatic charge of the particles and facilitate the manufacturing process. The content of the fluidizer or lubricant in the intermediate layer is preferably about 0.01 to 50% by weight based on the total amount of the drug-containing particles.
[0042] (Third aspect) The masked particles may also be drug-containing particles that have a portion containing an acid and a portion containing a carbonate, and are covered with a coating layer.
[0043] When the acid and carbonate are mixed in the same part, they will generate foam when dissolved, so water cannot be used in the manufacturing process, and the manufacturing method may be limited.Therefore, for example, a particulate composition can be made in which a drug-containing particle consisting of a core particle and an intermediate layer is coated with a coating layer, and the acid and carbonate can be mixed separately into either the core particle or the intermediate layer.In this case, since the acid and carbonate are present in different parts, each or either of the core particle and the intermediate layer can be formed using water, and in particular, the intermediate layer material can be used as a water-soluble solution for coating (intermediate layer formation). The acid and carbonate may be contained in either the core particle or the intermediate layer. However, from the viewpoint of ease of use of an acid-labile coating layer, it is preferred that the core particle contains the acid and the intermediate layer contains the carbonate. The drug may be blended in either the core particle or the intermediate layer, or in both. Blending the acid and the drug in separate parts makes it easy to use drugs that are sensitive to acids, and blending the carbonate and the drug in separate parts makes it easy to use drugs that are sensitive to alkalis.
[0044] In this embodiment, the core particle and the intermediate layer may further contain any additives used in granules, fine granules, powders, etc. The core particle preferably contains a disintegrant, and the intermediate layer preferably contains a binder, a flow agent, or a lubricant (anti-adhesive agent). The preferred types and contents of the disintegrant, binder, flow agent, or lubricant (anti-adhesive agent) are as described for the core particle and intermediate layer in the second embodiment.
[0045] In the third embodiment, the drug, acid, and carbonate can be contained in separate parts. In this case, since the acid and carbonate are present in separate parts, there is no need to restrict the use of water during production, and since the drug and acid, and the drug and carbonate are present in separate parts, it is easy to use drugs that are sensitive to acids or alkalis. For example, a drug-containing particle consisting of a core particle and two intermediate layers covering it can be coated with a coating layer, and a drug, an acid, and a carbonate can be separately blended in either the core particle, the inner intermediate layer (hereinafter sometimes referred to as the "first intermediate layer"), or the outer intermediate layer (hereinafter sometimes referred to as the "second intermediate layer"). Preferably, the core particle contains a drug, and the two intermediate layers can each contain an acid and a carbonate. Either the first intermediate layer or the second intermediate layer may contain an acid and a carbonate, but it is preferable that the first intermediate layer contains an acid, and the second intermediate layer contains a carbonate. Furthermore, the core particle can be made of a central core containing an excipient and a drug-containing layer surrounding it. Another intermediate layer consisting of an excipient can be provided between the part (or layer) containing the drug and the part (or layer) containing the acid or carbonate. In this case, the outer layer of the core particle may be called the first intermediate layer, the outer layer the second intermediate layer, and the outer layer the third intermediate layer.
[0046] In this embodiment, the core particle and each intermediate layer may further contain any additive used in tablets, granules, fine granules, powders, etc. The core particle preferably contains a disintegrant, and the preferred type and content of the disintegrant are as described for the core particle of the second embodiment. Each intermediate layer preferably contains a binder, a flow agent, or a lubricant (anti-adhesion agent), and the preferred types of the binder, flow agent, or lubricant (anti-adhesion agent) are as described for the intermediate layer of the second embodiment. When each intermediate layer contains a binder, the content is preferably 0.1 to 20% by weight in total relative to the total amount of the drug-containing particle. When each intermediate layer contains a flow agent or a lubricant (anti-adhesion agent), the content is preferably 0.01 to 50% by weight in total relative to the total amount of the drug-containing particle.
[0047] The masking particles of the present invention can be particles of various structures in addition to the first to third embodiments.
[0048] Manufacturing method In the masked particle of the present invention, the drug-containing particle, the core particle, and the central core of the excipient can be produced by wet or dry granulation according to a conventional method, followed by drying and sizing as necessary. Examples of the wet granulation method include fluidized bed granulation, stirring granulation, rolling granulation, extrusion granulation, crushing granulation, kneading granulation, continuous direct granulation, and composite fluidized bed granulation, while examples of the dry granulation method include dry composite granulation, pressing granulation, briquette granulation, and melt granulation. The intermediate layer and the coating layer can be produced in accordance with a conventional method using an apparatus such as a fluidized bed coater, a Wurster type fluidized bed coater, a centrifugal fluidized bed coater, or a tumbling fluidized bed coater.
[0049] Properties The shape of the drug-containing particles containing a drug, an acid, and a carbonate will vary depending on the granulation method, but can be spherical, cylindrical, oblong (elliptical), or the like. The particle size of the masking particles after being coated with the coating layer is not particularly limited, but may be D 50 It is preferable that the thickness is about 50 to 1000 μm, and more preferably about 100 to 800 μm. 50 may be 50 μm or more, 100 μm or more, 200 μm or more, or 300 μm or more, or may be 1000 μm or less, 800 μm or less, 600 μm or less, or 400 μm or less. 50 is a value calculated by measuring particle size according to the particle size measurement method using a laser diffraction method in the particle size measurement method of the Japanese Pharmacopoeia, 17th Edition, and specifically, is a value measured by the method described in the Examples section.
[0050] tablet The masked particle of the present invention can be used for tablet production.Therefore, the present invention also provides a tablet produced using the masked particle of the present invention.For example, the masked particle of the present invention can be directly compressed, or can be mixed with one or more additives and compressed to produce a tablet. The masked particles of the present invention can be suitably used for the production of orally disintegrating tablets because the taste of the drug felt in the mouth is masked. Various methods for producing orally disintegrating tablets are known, and a person skilled in the art can produce orally disintegrating tablets by appropriately selecting the type and amount of additives to be mixed with the masked particles of the present invention. When the masked particles of the present invention are mixed with additives to produce an orally disintegrating tablet, the content of the masked particles of the present invention can be 1% by weight or more, 5% by weight or more, or 10% by weight or more based on the total weight of the orally disintegrating tablet, and can be 90% by weight or less, 70% by weight or less, or 60% by weight or less.
[0051] Drug dissolution rate Although the dissolution rate of the masked particles of the present invention varies depending on the type of drug, it is preferable that the dissolution rate measured using a dissolution test solution of pH 6.8 according to the paddle method of the dissolution test method of the 17th Edition of the Japanese Pharmacopoeia is essentially zero (substantially no drug is dissolved) for at least 0.5 minutes, preferably at least 1 minute, preferably at least 1.5 minutes, and preferably at least 3 minutes after the start of the test. The masked particles of the present invention may have a drug release lag time of 0.5 minutes or more, 1 minute or more, or 3 minutes or more. The drug release lag time may be 15 minutes or less, 10 minutes or less, or 8 minutes or less. The drug release lag time is a value measured by the method described in the Examples section. In addition, the masked particles of the present invention preferably have a drug release rate of 1% / min or more, more preferably 2% / min or more, more preferably 10% / min or more, and more preferably 30% / min or more. In addition, the drug release rate may be 80% / min or less, 70% / min or less, or 60% / min or less. The drug release rate is a value measured by the method described in the Examples section.
[0052] Drug Release Control Method The present invention includes a method for delaying the elution or release of a drug from a drug-containing particle for a certain period of time by adding an acid and a carbonate to the drug-containing particle and coating the drug-containing particle containing the drug, acid, and carbonate with a coating layer containing a water-insoluble polymer, that is, a method for suppressing the elution or release of a drug for a certain period of time. In this method, the drug elution suppression time can be adjusted by adjusting the type, amount, and ratio of the acid, carbonate, and other components contained in the drug-containing particle; the amount of the coating layer; the type, amount, and ratio of the components contained in the coating layer. The type, amount, and ratio of the acid, carbonate, and other components contained in the drug-containing particle; the amount of the coating layer; the type, amount, and ratio of the components contained in the coating layer are as described for the masking particle of the present invention. Therefore, the present invention includes a method for controlling the elution or release of a drug from a drug-containing particle by adding an acid and a carbonate to the drug-containing particle and coating the drug-containing particle containing the drug, acid, and carbonate with a coating layer containing a water-insoluble polymer. EXAMPLES
[0053] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these. (1) Test method (Dissolution test) Dissolution tests were performed according to the Japanese Pharmacopoeia Dissolution Test Method 2. The paddle rotation speed was set to 50 rpm, and 900 mL of pH 6.8 phosphate buffer (Japanese Pharmacopoeia Disintegration Test Method 2 Fluid) was used as the test solution. Drug-containing particles or masking particles or tablets containing 250 mg of levofloxacin were placed in the vessel. 10 mL of each sample was taken from each vessel at 1, 2, 3, 5, 10, 15, 30, 45, and 90 minutes of testing, and the dissolution rate was calculated by ultraviolet-visible absorbance measurement. This was repeated three times, and the average value was calculated as the average dissolution rate.
[0054] (Particle size distribution measurement) In the present invention, the particle size was measured on a volume basis using a laser diffraction particle size distribution measuring device (manufactured by Malvern).
[0055] (2) Effect of the coating layer Examples 1 to 5 Drug-containing particles having core particles containing levofloxacin hydrate and citric acid hydrate and an intermediate layer containing sodium bicarbonate, and masked particles coated with the drug-containing particles were prepared as follows. [Preparation of core particles] 400 g of levofloxacin hydrate, 240 g of pulverized citric acid hydrate (manufactured by Satsuma Kako Co., Ltd., the same applies below), and 160 g of low-substituted hydroxypropyl cellulose (manufactured by Shin-Etsu Chemical Co., Ltd.; LHPC31, the same applies below) were charged into a stirring and mixing granulation device (manufactured by Powrex Corporation; Vertical Granulator FM-VG-05, the same applies below) and mixed, and then 560 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded product. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran (MG-55-2, manufactured by DALTON, hereinafter the same), and sized using a spherical granulator Marumerizer (QJ-230T-2, manufactured by DALTON, hereinafter the same).Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of intermediate layer coating solution (1)] 12 g of hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd.; HPCL; the same hereinafter) was dissolved in 400 g of absolute ethanol (manufactured by Japan Alcohol Industry Co., Ltd.; the same hereinafter), to which 25 g of talc (manufactured by Hayashi Kasei Co., Ltd.; Talcan Hayashi; the same hereinafter) and 45 g of pulverized sodium bicarbonate (manufactured by AGC Inc.; the same hereinafter) were added and stirred to prepare a coating solution (1) for forming an intermediate layer. [Preparation of drug-containing particles] 150 g of the obtained core particles were placed in a tumbling fluidized coating device (Multiplex, manufactured by Powrex Corporation, the same applies below), and the coating liquid (1) was sprayed onto the core particles to obtain drug-containing particles coated with 82 g of an intermediate layer. [Preparation of masking coating liquid (2)] 30 g of aminoalkyl methacrylate copolymer E (Eudragit E, manufactured by Evonik Nutrition & care GmbH, hereinafter the same) was dissolved in a mixture of 270 g of ethanol and 30 g of purified water, 30 g of talc was added, and the mixture was stirred to prepare a coating solution (2) for masking. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer (a coating layer containing a water-insoluble polymer is called a masking layer; the same applies below) to the mass of the drug-containing particles was 6% in Example 1, 12% in Example 2, 18% in Example 3, 24% in Example 4, and 30% in Example 5.
[0056] Comparative Example 1 Drug-containing particles were prepared in the same manner as in Examples 1 to 5, and used as Comparative Example 1.
[0057] Dissolution tests were carried out for Examples 1 to 5 and Comparative Example 1. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 1. The upper part of Figure 1 shows the results for 30 minutes after the start of the test, and the lower part shows the results for 90 minutes after the start of the test. In Comparative Example 1, the drug was released quickly due to foaming, but there was no lag time for drug release because there was no coating layer containing a water-insoluble polymer. On the other hand, in Examples 1 to 5, after the water infiltration was prevented for a certain period of time by the coating layer containing a water-insoluble polymer, water penetrated inside, and the drug was released quickly due to the membrane destruction from the inside caused by foaming. As a result, a lag time of 1 to 5.9 minutes and a rapid drug release of 2.3 to 50.9% / min were both achieved.
[0058] The drug release lag time was the time required for 1% of the drug to be released in a dissolution test at pH 6.8, and was calculated from two measurement points straddling 1%. The drug release rate was calculated from the first two measurement points at which the dissolution rate was measured in the range of 3 to 90% in the dissolution test at pH 6.8.
[0059] (3) Effects of Acid Comparative Example 2 Drug-containing particles were prepared in the same manner as in Comparative Example 1, except that citric acid hydrate was changed to erythritol (manufactured by Bussan Food Sciences; Erythritol 100M, the same applies below), and this was used as Comparative Example 2. Comparative Example 3 190 g of the drug-containing particles of Comparative Example 2 were placed in a tumbling fluidized coating device and sprayed with coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 18%, similar to Example 3. Comparative Example 3 is the same as Example 3 except that the citric acid hydrate in the core particles of Example 3 was changed to erythritol.
[0060] Dissolution tests were carried out on the masked particles of Example 3, the drug-containing particles of Comparative Example 2, and the masked particles of Comparative Example 3. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 2. The upper row of Figure 2 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. In Comparative Example 2, the drug release was rapid like in Comparative Example 1, but there was no lag time because there was no coating layer containing a water-insoluble polymer. In Comparative Example 3, there was a lag time of 6.5 minutes due to the coating layer containing a water-insoluble polymer, but because there was no membrane destruction due to foaming, the drug was released by gradual diffusion. As a result, the drug release rate was slow and the drug was not sufficiently dissolved even 90 minutes after the start of the test. It is clear that the acid is essential for rapid drug release after the drug release is inhibited.
[0061] (4) Type of water-insoluble polymer in the coating layer Examples 6 and 7 [Preparation of masking coating solution (3)] 40 g of ethyl cellulose (manufactured by The Dow Chemical; Ethocel Standard 7 Premium, the same applies below) was dissolved in a mixture of 720 g of ethanol and 80 g of purified water, 40 g of talc was added, and the mixture was stirred to prepare a coating liquid (3). [Preparation of masking particles] 200 g of the drug-containing particles of Comparative Example 1 were placed in a tumbling fluidized bed coating device, and the coating liquid (3) was sprayed onto them to obtain masked particles. Example 6 had a masking layer mass ratio of 9% to the drug-containing particles, and Example 7 had a masking layer mass ratio of 12%.
[0062] A dissolution test was carried out on the masked particles of Examples 6 and 7. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 3. The upper part of Figure 3 shows the results for 30 minutes after the start of the test, and the lower part shows the results for 90 minutes after the start of the test. In Examples 6 and 7, the coating layer containing the water-insoluble polymer prevented water from entering for a certain period of time, after which water penetrated inside and foaming caused membrane destruction from the inside, releasing the drug quickly. As a result, both a lag time of 1.4 to 5.4 minutes and a rapid drug release rate of 3.7 to 5.1% / min were achieved. The water-soluble polymer in the coating layer of Examples 6 and 7 was ethyl cellulose, which was different from the aminoalkyl methacrylate copolymer E of Examples 1 to 5. In Examples 6 and 7, a slower drug release rate was obtained after the lag time had elapsed compared to Examples 1 to 5. It is clear that drug release can be inhibited for a certain period of time and then rapidly released, regardless of the type of water-insoluble polymer. It is also clear that the drug release inhibition time and the subsequent drug release rate can be adjusted by selecting the type of water-insoluble polymer.
[0063] (5) Amount of acid and carbonate Examples 8 to 11 [Preparation of core particles] 422.5 g of levofloxacin hydrate, 97.5 g of pulverized citric acid hydrate, and 130 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator, and after mixing, 565.5 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded product. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] 200 g of the obtained core particles were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with 54.7 g of an intermediate layer. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 12% in Example 8, 18% in Example 9, 24% in Example 10, and 30% in Example 11.
[0064] Comparative Example 4 Drug-containing particles were prepared in the same manner as in Examples 8 to 11, and used as Comparative Example 4.
[0065] Examples 12 to 15 [Preparation of core particles] 487.5 g of levofloxacin hydrate, 32.5 g of pulverized citric acid hydrate, and 130 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator, and after mixing, 560 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] The obtained core particles (150 g) were placed in a tumbling fluidized bed coating apparatus and sprayed with the coating liquid (1) to obtain drug-containing particles coated with 13.7 g of an intermediate layer. [Preparation of masking particles] 150 g of the obtained drug-containing particles were placed in a tumbling fluidized bed coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 12% in Example 12, 18% in Example 13, 24% in Example 14, and 30% in Example 15.
[0066] Comparative Example 5 Drug-containing particles were prepared in the same manner as in Examples 12 to 15, and used as Comparative Example 5.
[0067] Dissolution tests were conducted on the masked particles of Examples 8 to 11, the drug-containing particles of Comparative Example 4, the masked particles of Examples 12 to 15, and the drug-containing particles of Comparative Example 5. The time course of the dissolution rate of levofloxacin hydrate from the masked particles of Examples 8 to 11 and the drug-containing particles of Comparative Example 4 is shown in Figure 4, and the time course of the dissolution rate from the masked particles of Examples 12 to 15 and the drug-containing particles of Comparative Example 5 is shown in Figure 5. The upper rows of Figures 4 and 5 show the results for 30 minutes after the start of the test, and the lower rows show the results for 90 minutes after the start of the test.
[0068] In Examples 1 to 5, the citric acid hydrate content per tablet is 153.8 mg, and the sodium bicarbonate content is 153.8 mg. In contrast, in Examples 8 to 11, the citric acid hydrate content is 59.1 mg, and the sodium bicarbonate content is 59.1 mg, which is low, and in Examples 12 to 15, the citric acid hydrate content is 17.1 mg, and the sodium bicarbonate content is even lower, at 17.1 mg.
[0069] In Comparative Examples 4 and 5, the drug was released quickly due to effervescence, but there was no lag time due to the absence of a coating layer containing a water-insoluble polymer. In contrast, in Examples 8 to 11 and Examples 12 to 15, after the water infiltration was prevented for a certain period of time by the coating layer containing a water-insoluble polymer, water penetrated inside, and the drug was released quickly due to the membrane destruction from the inside caused by foaming. As a result, in Examples 8 to 11, a lag time of 1 to 4.2 minutes and a rapid drug release rate of 9.7 to 34.5% / min were both achieved. Also, in Examples 12 to 15, a lag time of 1 to 3.4 minutes and a rapid drug release rate of 3.5 to 34.3% / min were both achieved. It is clear that a wide range of the amounts of acid and carbonate can be used to suppress drug release for a certain period of time, followed by rapid drug release. It is also clear that the drug release suppression time and drug release rate can be controlled by adjusting the amounts of acid and carbonate.
[0070] (6) Type of binder Example 16 [Preparation of intermediate layer coating solution (4)] 12 g of polyethylene glycol (Macrogol 6000 by Sanyo Chemical Industries, Ltd., the same applies below) was dissolved in 171 g of absolute ethanol, to which 25 g of talc and 45 g of ground sodium bicarbonate were added and stirred to prepare a coating solution (4). [Preparation of drug-containing particles] 150 g of the same core particles as those in Examples 1 to 5 and Comparative Example 1 were placed in a tumbling fluidized coating device, and the coating liquid (4) was sprayed onto them to obtain drug-containing particles coated with 82 g of an intermediate layer. [Preparation of masking particles] The obtained drug-containing particles (190 g) were placed in a tumbling fluidized bed coating device and sprayed with coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the drug-containing particles was 18%.
[0071] Comparative Example 6 Drug-containing particles were prepared in the same manner as in Example 16 and used as Comparative Example 6.
[0072] A dissolution test was carried out on the masked particles of Example 16 and the drug-containing particles of Comparative Example 6. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 6. The upper row of Figure 6 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. In Example 16, the hydroxypropyl cellulose in the middle layer of Example 3 was replaced with polyethylene glycol. In Example 16, after the water infiltration was prevented for a certain period of time by the coating layer containing a water-insoluble polymer, water penetrated the inside, and the drug was released quickly due to the membrane destruction from the inside caused by foaming. As a result, both a lag time of 2.1 minutes and a rapid drug release rate of 13.2% / min were achieved. It can be seen that it is possible to suppress drug release for a certain period of time and then achieve rapid drug release, regardless of the type of binder. On the other hand, in Comparative Example 6, the drug was released quickly due to effervescence, but there was no lag time due to the absence of a coating layer containing a water-insoluble polymer.
[0073] (7) Alteration of acid- and carbonate-containing layers Examples 17 to 20 [Preparation of core particles] 375 g of levofloxacin hydrate, 225 g of pulverized sodium hydrogen carbonate, and 150 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer granulator, mixed, and then 525 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of intermediate layer coating solution (5)] 16 g of hydroxypropyl cellulose was dissolved in 960 g of absolute ethanol, to which 33.3 g of talc and 60 g of citric acid hydrate were added and stirred to prepare a coating liquid (5). [Preparation of drug-containing particles] The obtained core particles (200 g) were placed in a tumbling fluidized bed coating apparatus and the coating liquid (5) was sprayed onto the core particles to obtain drug-containing particles coated with 109.3 g of an intermediate layer. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized bed coating device and sprayed with coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the drug-containing particles was 30%.
[0074] Examples 18 to 20 [Preparation of masking particles] 200 g of the same drug-containing particles as in Example 17 were placed in a tumbling fluidized coating apparatus and sprayed with coating liquid (3) to obtain masked particles. Example 18 has a masking layer with a mass ratio of 6% to the mass of the drug-containing particles, Example 19 has a masking layer with a mass ratio of 12%, and Example 20 has a masking layer with a mass ratio of 18%.
[0075] Comparative Example 7 Drug-containing particles were prepared in the same manner as in Examples 17 to 20, and used as Comparative Example 7.
[0076] Dissolution tests were carried out on the masked particles of Examples 17 to 20 and the drug-containing particles of Comparative Example 7. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 7. The upper row of Figure 7 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. In Examples 17 to 20, unlike Examples 1 to 16, the core particles contain sodium bicarbonate and the intermediate layer contains citric acid hydrate. In Examples 17 to 20, a lag time of 1 to 5.1 minutes and a rapid drug release rate of 3.4 to 30.4% / min were also achieved. It can be seen that even if the part containing the acid and carbonate is changed, it is possible to achieve inhibition of drug release for a certain period of time and subsequent rapid drug release. On the other hand, in Comparative Example 7, the drug was released quickly due to effervescence, but there was no lag time due to the absence of a coating layer containing a water-insoluble polymer.
[0077] The compositions of the drug-containing particles of Examples 1 to 20 and Comparative Examples 1 to 7 are shown in Table 1. [Table 1]
[0078] (8) Disintegrant content Example 21 [Preparation of core particles] 325 g of levofloxacin hydrate, 195 g of pulverized citric acid hydrate, 32.5 g of low-substituted hydroxypropylcellulose, and 97.5 g of erythritol were charged into a stirring mixer and granulator and mixed, and then 195 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded product. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] 200 g of the above obtained core particles were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with 109.3 g of an intermediate layer. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 18% by weight.
[0079] Comparative Example 8 Drug-containing particles were prepared in the same manner as in Example 21 and designated as Comparative Example 8.
[0080] A dissolution test was carried out on the masked particles of Example 21 and the drug-containing particles of Comparative Example 8. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 8. The upper row of Figure 8 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. Example 21 is a formulation in which the amount of low-substituted hydroxypropyl cellulose in Example 3 is reduced to 1 / 4, with the remainder replaced with erythritol. Example 21 also achieved both a lag time of 3.1 minutes and a rapid drug release rate of 9.0% / min. It can be seen that even with a small amount of disintegrant, inhibition of drug release for a certain period of time and subsequent rapid drug release can be achieved. On the other hand, in Comparative Example 8, the drug was released quickly due to effervescence, but there was no lag time due to the absence of a coating layer containing a water-insoluble polymer.
[0081] (9) Acid and carbonate content ratio Examples 22 to 24 [Preparation of core particles] 400 g of levofloxacin hydrate, 240 g of pulverized citric acid hydrate, and 160 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator and mixed, and then 560 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] 200 g of the obtained core particles were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with 54.7 g of an intermediate layer. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 18% in Example 22, 24% in Example 23, and 30% in Example 24.
[0082] Comparative Example 9 Drug-containing particles were prepared in the same manner as in Examples 22 to 24 and designated as Comparative Example 9.
[0083] Examples 25 to 27 [Preparation of core particles] 400 g of levofloxacin hydrate, 240 g of pulverized citric acid hydrate, and 160 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator and mixed, and then 560 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] The obtained core particles (200 g) were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto the core particles to obtain drug-containing particles coated with an intermediate layer (18.23 g). [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 18% in Example 25, 24% in Example 26, and 30% in Example 27.
[0084] Comparative Example 10 Drug-containing particles were prepared in the same manner as in Examples 25 to 27 and designated as Comparative Example 10.
[0085] Examples 28 to 30 [Preparation of core particles] 390 g of levofloxacin hydrate, 90 g of pulverized citric acid hydrate, and 180 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator and mixed, and then 480 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] 200 g of the obtained core particles were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with 109.3 g of an intermediate layer. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. Example 28 had a masking layer mass ratio of 12% relative to the mass of the drug-containing particles, Example 29 had a masking layer mass ratio of 18%, and Example 30 had a masking layer mass ratio of 24%.
[0086] Comparative Example 11 Drug-containing particles were prepared in the same manner as in Examples 28 to 30 and used as Comparative Example 11.
[0087] Examples 31 to 33 [Preparation of core particles] 390 g of levofloxacin hydrate, 90 g of pulverized citric acid hydrate, and 180 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator and mixed, and then 480 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] The obtained core particles (200 g) were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto the core particles to obtain drug-containing particles coated with an intermediate layer (18.23 g). [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 18% in Example 31, 24% in Example 32, and 30% in Example 33.
[0088] Comparative Example 12 Drug-containing particles were prepared in the same manner as in Examples 31 to 33 and used as Comparative Example 12.
[0089] Example 34 [Preparation of core particles] 600 g of levofloxacin hydrate, 40 g of pulverized citric acid hydrate, and 160 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator and mixed, and then 560 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] 200 g of the obtained core particles were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with 109.3 g of an intermediate layer. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 12%.
[0090] Comparative Example 13 Drug-containing particles were prepared in the same manner as in Example 34 and used as Comparative Example 13.
[0091] Examples 35 to 36 [Preparation of core particles] 600 g of levofloxacin hydrate, 40 g of pulverized citric acid hydrate, and 160 g of low-substituted hydroxypropylcellulose were charged into a stirring mixer and granulator and mixed, and then 560 g of purified water was sprayed onto the mixture while stirring to obtain a kneaded mixture. Next, the kneaded mixture was extrusion granulated using a wet extrusion granulator Multigran, and sized using a spherical granulator Marumerizer.Then, the particles passed through a 30 (500 μm) mesh and those remaining on a 42 (355 μm) mesh were used as core particles. [Preparation of drug-containing particles] 200 g of the obtained core particles were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with 54.7 g of an intermediate layer. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. Example 35 had a masking layer mass ratio of 12% to the drug-containing particles, and Example 36 had a masking layer mass ratio of 18%.
[0092] Comparative Example 14 Drug-containing particles were prepared in the same manner as in Examples 35 and 36, and used as Comparative Example 14.
[0093] For the masked particles of Examples 22 to 36 and the drug-containing particles of Comparative Examples 9 to 14, dissolution tests were carried out. The time course of the dissolution rate of levofloxacin hydrate is shown in Figures 9 to 14. Figure 9 shows the results for the masked particles of Examples 22 to 24 and the drug-containing particles of Comparative Example 9, Figure 10 shows the results for the masked particles of Examples 25 to 27 and the drug-containing particles of Comparative Example 10, Figure 11 shows the results for the masked particles of Examples 28 to 30 and the drug-containing particles of Comparative Example 11, Figure 12 shows the results for the masked particles of Examples 31 to 33 and the drug-containing particles of Comparative Example 12, Figure 13 shows the results for the masked particles of Example 34 and the drug-containing particles of Comparative Example 13, and Figure 14 shows the results for the masked particles of Examples 35 to 36 and the drug-containing particles of Comparative Example 14. The upper rows of Figures 9 to 14 show the results for 30 minutes after the start of the test, and the lower rows show the results for 90 minutes after the start of the test.
[0094] In Examples 22 to 24, the amount of sodium hydrogen carbonate blended was halved from that in Examples 3 to 5. That is, the weight ratio of sodium hydrogen carbonate to 1 part by weight of citric acid hydrate was 1 part by weight in Examples 3 to 5, whereas it was 0.5 parts by weight in Examples 22 to 24. In Examples 25 to 27, the amount of sodium hydrogen carbonate blended was 1 / 6 of that in Examples 3 to 5. That is, the weight ratio of sodium hydrogen carbonate to 1 part by weight of citric acid hydrate was 1 part by weight in Examples 3 to 5, whereas it was 0.17 parts by weight in Examples 25 to 27. In Examples 28 to 30, the amount of sodium hydrogen carbonate was doubled compared to Examples 9 to 11. That is, the weight ratio of sodium hydrogen carbonate to 1 part by weight of citric acid hydrate was 1 part by weight in Examples 9 to 11, whereas it was 2 parts by weight in Examples 28 to 30. In Examples 31 to 33, the amount of sodium hydrogen carbonate blended was 1 / 3 of that in Examples 9 to 11. That is, the weight ratio of sodium hydrogen carbonate to 1 part by weight of citric acid hydrate was 1 part by weight in Examples 9 to 11, whereas it was 0.33 parts by weight in Examples 31 to 33. In Example 34, the amount of sodium hydrogen carbonate was six times that of Example 12. That is, the weight ratio of sodium hydrogen carbonate to 1 part by weight of citric acid hydrate is 1 part by weight in Example 12, whereas it is 6 parts by weight in Example 34. In Examples 35 and 36, the amount of sodium hydrogen carbonate blended was three times that of Examples 12 and 13. That is, the weight ratio of sodium hydrogen carbonate to 1 part by weight of citric acid hydrate was 1 part by weight in Examples 12 and 13, whereas it was 3 parts by weight in Examples 35 and 36.
[0095] In Examples 22-24, a lag time of 1.3-2.6 minutes and a rapid drug release rate of 14.8-27.3% / min were both achieved (Figure 9). In Examples 25-27, a lag time of 1.1-2.2 minutes and a rapid drug release rate of 10.8-13.3% / min were both achieved (Figure 10). In Examples 28-30, a lag time of 1.3-3.1 minutes and a rapid drug release rate of 3.5-14.7% / min were both achieved (Figure 11). In Examples 31-33, a lag time of 1.6-1.8 minutes and a rapid drug release rate of 4.1-21.8% / min were both achieved (Figure 12). In Example 34, a lag time of 2.0 minutes and a rapid drug release rate of 7.5% / min were both achieved (Figure 13). In Examples 35 to 36, a lag time of 1.4 to 2.5 minutes and a rapid drug release rate of 5.2 to 18.7% / min were both achieved (FIG. 14). A constant drug release inhibition time and rapid drug release were obtained over a wide range of 0.17 to 6 parts by weight of carbonate per part by weight of acid. On the other hand, in Comparative Examples 9 to 14, the drug was released quickly due to effervescence, but there was no lag time due to the absence of a coating layer containing a water-insoluble polymer.
[0096] The compositions of the drug-containing particles of Examples 21 to 36 and Comparative Examples 8 to 14 are shown in Table 2. [Table 2]
[0097] (10) Structure of drug-containing particles Drug-containing particles with a core particle and two intermediate layers Examples 37 to 39 [Preparation of Coating Liquid (6)] 60 g of citric acid hydrate was added to 857 g of absolute ethanol and stirred to prepare a coating liquid (6). [Preparation of intermediate layer I particles] 200 g of the core particles of Comparative Example 2 were placed in a tumbling fluidized coating device, and the coating liquid (6) was sprayed onto the core particles to obtain intermediate layer I particles coated with 60 g of intermediate layer I. [Preparation of drug-containing particles] 200 g of the obtained intermediate layer I particles were placed in a tumbling fluidized coating device and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with 84.1 g of intermediate layer II. [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 30% in Example 37, 36% in Example 38, and 42% in Example 39.
[0098] Comparative Example 15 Drug-containing particles were prepared in the same manner as in Examples 37-39 and used as Comparative Example 15.
[0099] For the masked particles of Examples 37 to 39 and the drug-containing particles of Comparative Example 15, a dissolution test was carried out. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 15. The upper part of Figure 15 shows the results for 30 minutes after the start of the test, and the lower part shows the results for 90 minutes after the start of the test. In Examples 37 to 39, drug-containing core particles were coated with an intermediate layer I containing citric acid hydrate, which was then coated with an intermediate layer containing sodium bicarbonate, and the resulting drug-containing particles were then covered with a coating layer containing a water-insoluble polymer. In Examples 37 to 39, a lag time of 1.3 to 2.2 minutes and a rapid drug release rate of 6.0 to 17.5% / min were both achieved. Even when using drug-containing particles that contain a drug, an acid, and a carbonate in separate portions, the drug release inhibition time and drug release rate could be appropriately controlled. Masking particles with this structure can also be used suitably for drugs that are unstable in acids or alkalis. Furthermore, the content ratio of the coating layer to the drug-containing particles was 30-42 wt %, which is higher than the 6-30 wt % in Examples 1-36, but an appropriate lag time and drug release rate were obtained.
[0100] Drug-coated core particles and drug-containing particles with three intermediate layers Examples 40 to 42 [Preparation of core particles] 1000 g of D-mannitol spherical granules (Nonpareil 108 (100) by Freund Corporation, the same applies below) were passed through a 100 (150 μm) mesh and those remaining on a 200 (75 μm) mesh were used as core particles. [Preparation of Coating Liquid (7)] Hypromellose (TC-5R, manufactured by Shin-Etsu Chemical Co., Ltd.; the same applies below) was added and dissolved in a mixture of 158 g of purified water and 68 g of absolute ethanol, and then 45 g of levofloxacin hydrate was added and stirred to prepare a coating solution (7). [Adjustment of drug layer particles] 593.7 g of the above core particles were placed in a tumbling fluidized bed coating apparatus, and the coating liquid (7) was sprayed onto the core particles to obtain 56.3 g of drug layer-coated drug layer particles. [Preparation of Coating Liquid (8)] To 276 g of purified water, 45 g of D-mannitol (ROQUETTE; PEALITOL 50C, the same applies below) was added and stirred to prepare a coating liquid (8). [Adjustment of intermediate layer I particles] 150 g of the above drug layer particles were placed in a tumbling fluidized bed coating device, and the coating liquid (8) was sprayed onto the particles to obtain intermediate layer I particles coated with 45 g of intermediate layer I. [Preparation of Coating Liquid (9)] To a mixture of 420 g of purified water and 180 g of absolute ethanol, 60 g of citric acid hydrate and 30 g of D-mannitol were added and stirred to prepare a coating liquid (9). [Preparation of intermediate layer II particles] 125 g of the above intermediate layer I particles were placed in a tumbling fluidized coating device, and the coating liquid (9) was sprayed onto the particles to obtain intermediate layer II particles coated with 43.3 g of intermediate layer II. [Preparation of drug-containing particles] The obtained intermediate layer II particles (125 g) were placed in a tumbling fluidized bed coating apparatus and the coating liquid (1) was sprayed onto them to obtain drug-containing particles coated with an intermediate layer III (117.2 g). [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized coating device and sprayed with the coating liquid (2) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 54% in Example 40, 66% in Example 41, and 78% in Example 42.
[0101] Comparative Example 16 Drug-containing particles were prepared in the same manner as in Examples 40 to 42 and used as Comparative Example 16.
[0102] Dissolution tests were carried out on the masked particles of Examples 40 to 42 and the drug-containing particles of Comparative Example 16. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 16. The upper row of Figure 16 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. In Examples 40 to 42, excipient core particles having a drug-containing coating are coated with an intermediate layer I made of an excipient, which is then coated with an intermediate layer II containing citric acid hydrate, which is then coated with an intermediate layer III containing sodium bicarbonate, and the resulting drug-containing particles are then coated with a coating layer containing a water-insoluble polymer.In Examples 40 to 42, a lag time of 1.0 to 2.0 minutes and a rapid drug release rate of 10.9 to 27.2% / min were both achieved. By providing an intermediate layer between the drug-containing layer and the acid-containing layer or carbonate-containing layer, it was possible to appropriately control the drug release inhibition time and drug release rate even when using drug-containing particles in which the drug does not come into contact with the acid or carbonate at all. Masking particles with this structure can also be used suitably for drugs that are extremely unstable in acids or alkalis. Furthermore, the content ratio of the coating layer to the drug-containing particles was 54-78 wt %, which is much higher than the 6-30 wt % in Examples 1-36, but an appropriate lag time and drug release rate were obtained. In addition, the masking particles in Examples 40 to 42 use smaller core particles than those in Examples 1 to 39, and therefore the masking particles are also finer. This technology can appropriately control the drug release inhibition time and drug release rate regardless of the particle size of the masking particles.
[0103] The compositions of the drug-containing particles of Examples 37-39 and Comparative Example 15 are shown in Table 3, and the compositions of the drug-containing particles of Examples 40-42 and Comparative Example 16 are shown in Table 4. [Table 3]
[0104] [Table 4]
[0105] From the above, it can be seen that masking particles in which drug-containing particles containing a drug, acid, and carbonate are covered with a coating layer containing a water-insoluble polymer can provide an appropriate lag time and a rapid drug release rate, regardless of the composition of the drug-containing particles.
[0106] (11) Manufacturing of orally disintegrating tablets using masked particles Example 43 [Preparation of fast-disintegrating granules] 374.5 g of D-mannitol, 10.5 g of ethyl cellulose, and 5.3 g of light anhydrous silicic acid were placed in a fluidized bed granulator and granulated with a granulation liquid prepared by dispersing 105.5 g of corn starch and 31.6 g of crospovidone in 453.6 g of purified water to prepare rapidly disintegrating granules. [Preparation of tablets] 935.6 mg of the masked particles of Example 3 and 916.79 mg of the above rapidly disintegrating particles were mixed, and then 18.71 mg of magnesium stearate was added and mixed. The mixture was then placed in a single punch tablet press (Ichihashi Seiki Co., Ltd.; HANDTAB-200) and compressed using a 16 mm punch to obtain tablets with a thickness of 10.5 mm.
[0107] Dissolution tests were carried out on the orally disintegrating tablet of Example 43, the masked particles of Example 3 (particles coated with a 18% by weight masking layer relative to the drug-containing particles of Comparative Example 1), and the drug-containing particles of Comparative Example 1. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 17. The upper row of Figure 17 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. The tablet of Example 43 showed almost the same dissolution profile as the masked particles of Example 3. It can be seen that the masked particles of the present invention can be used to manufacture tablets, and the obtained tablets have suppressed drug release in the mouth and then rapidly release the drug.
[0108] The composition of the orally disintegrating tablet of Example 43 is shown in Table 5. [Table 5]
[0109] (12) Types of acids and drugs Example 44 [Preparation of core particles] 1000 g of D-mannitol spherical granules were passed through a 100 (150 μm) mesh and those remaining on a 200 (75 μm) mesh were used as core particles. [Preparation of drug layer particles] 593.7 g of the above core particles were placed in a tumbling fluidized bed coating apparatus, and the coating liquid (7) was sprayed onto the particles to obtain drug layer particles coated with 56.3 g of the drug layer. [Preparation of intermediate layer I particles] 150 g of the above drug layer particles were placed in a tumbling fluidized bed coating device, and the coating liquid (8) was sprayed onto the particles to obtain intermediate layer I particles coated with 45 g of intermediate layer I. [Preparation of Coating Liquid (10)] To a mixture of 420 g of purified water and 180 g of absolute ethanol, 60 g of succinic acid (Wako Pure Chemical Industries, Ltd.) and 30 g of D-mannitol were added and stirred to prepare a coating liquid (10). [Preparation of intermediate layer II particles] 125 g of the above intermediate layer I particles were placed in a tumbling fluidized coating device, and the coating liquid (10) was sprayed onto the particles to obtain intermediate layer II particles coated with 43.3 g of intermediate layer II. [Preparation of drug-containing particles] 125 g of the above intermediate layer II particles were placed in a tumbling fluidized bed coating apparatus, and the coating liquid (1) was sprayed onto the particles to obtain drug-containing particles coated with 117.2 g of intermediate layer III. [Preparation of Coating Liquid (11)] 30 g of aminoalkyl methacrylate copolymer E was dissolved in a mixture of 210 g of ethanol and 90 g of purified water, 30 g of talc was added, and the mixture was stirred to prepare a coating liquid (11). [Preparation of masking particles] 200 g of the obtained drug-containing particles were placed in a tumbling fluidized bed coating device and sprayed with the coating liquid (11) to obtain masked particles. The mass ratio of the masking layer to the mass of the drug-containing particles was 54% by weight.
[0110] Comparative Example 17 Drug-containing particles were prepared in the same manner as in Example 44 and designated as Comparative Example 17.
[0111] A dissolution test was carried out on the masked particles of Example 44 and the drug-containing particles of Comparative Example 17. The time course of the dissolution rate of levofloxacin hydrate is shown in Figure 18. The upper row of Figure 18 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. In Example 44, a core particle not containing a drug is coated with a drug layer, which is then coated with an intermediate layer I made of an excipient, which is then coated with an intermediate layer II containing an acid, which is then coated with an intermediate layer III containing a carbonate. In Example 44, a lag time of 1.1 minutes and a rapid drug release rate of 22.7% / min were both achieved. On the other hand, in Comparative Example 17, there was no lag time because there was no coating layer containing a water-soluble polymer. The masked particles of Example 44 are the masked particles of Example 42, in which citric acid is replaced with succinic acid. Although succinic acid has a pKa of 4.2 / 5.6, which is a weaker acid than citric acid, which has a pKa of 3.1 / 4.8 / 6.4, the same effect is obtained. Thus, the acid in the present technology is not limited to a specific type as long as it is stronger than carbonic acid. Also, the masked particles of Example 44 are more useful for drugs that are unstable to acids or alkalis, since the drug does not come into direct contact with the acid and carbonate. In addition, the masking particles in Example 44 use smaller core particles than those in Examples 1 to 39, and therefore the masking particles are also finer. This technology can appropriately control the drug release inhibition time and drug release rate regardless of the particle size of the masking particles.
[0112] Example 45 [Preparation of core particles] 1000 g of D-mannitol spherical granules were passed through a 100 (150 μm) mesh and those remaining on a 200 (75 μm) mesh were used as core particles. [Preparation of Coating Liquid (12)] Hypromellose was added and dissolved in a mixture of 770 g of purified water and 330 g of absolute ethanol, and then 220 g of zolpidem tartrate was added and stirred to prepare a coating solution (12). [Preparation of drug layer particles] 358 g of the above core particles were placed in a tumbling fluidized bed coating apparatus, and the coating liquid (12) was sprayed onto the core particles to obtain 275 g of drug layer-coated drug layer particles. [Preparation of Coating Liquid (13)] 15.36 g of D-mannitol and 30.72 g of ground tartaric acid (manufactured by Kosakai Pharmaceutical Co., Ltd., the same applies below) were added to 307 g of purified water and stirred to prepare a coating liquid (13). [Preparation of intermediate layer I particles] 184.3 g of the above drug layer particles were placed in a tumbling fluidized bed coating device, and the coating liquid (13) was sprayed onto the particles to obtain intermediate layer I particles coated with 46.08 g of intermediate layer I. [Preparation of Coating Liquid (14)] 54 g of D-mannitol was added to 338 g of purified water and stirred to prepare a coating liquid (14). [Preparation of intermediate layer II particles] 180 g of the above intermediate layer I particles were placed in a tumbling fluidized coating device, and the coating liquid (14) was sprayed onto the particles to obtain intermediate layer II particles coated with 54 g of intermediate layer II. [Preparation of Coating Liquid (15)] 6.7 g of HPCL was dissolved in 135 g of absolute ethanol, to which 13.5 g of talc (Microace, manufactured by Nippon Talc Co., Ltd.) and 24.8 g of ground sodium hydrogen carbonate were added and stirred to prepare a coating solution (15). [Preparation of drug-containing particles] The above intermediate layer II particles (210 g) were placed in a tumbling fluidized bed coating device, and the coating liquid (15) was sprayed onto the particles to obtain drug-containing particles coated with an intermediate layer III (45 g). [Preparation of Coating Liquid (16)] 92 g of aminoalkyl methacrylate copolymer E was dissolved in a mixture of 644 g of ethanol and 276 g of purified water, and 0.92 g of yellow ferric oxide (Kishi Chemical Industries, Ltd.) and 276 g of talc (Microace, manufactured by Nippon Talc Co., Ltd.) were added thereto and stirred to prepare a coating liquid (16). [Preparation of masking particles] The obtained drug-containing particles (227.2 g) were placed in a tumbling fluidized bed coating apparatus and sprayed with the coating liquid (16) to obtain masked particles. Those that passed through a 60 (250 μm) mesh and remained on a 83 (180 μm) mesh were selected. The mass ratio of the masking layer to the mass of the drug-containing particles was 90% by weight.
[0113] Comparative Example 18 Drug-containing particles were prepared in the same manner as in Example 45 and designated as Comparative Example 18.
[0114] A dissolution test was carried out on the masked particles of Example 45 and the drug-containing particles of Comparative Example 18. The time course of the dissolution rate of zolpidem tartrate is shown in Figure 19. The upper row of Figure 19 shows the results for 30 minutes after the start of the test, and the lower row shows the results for 90 minutes after the start of the test. In Example 45, a drug-free core particle is coated with a drug layer, which is then coated with an intermediate layer I containing an acid, which is then coated with an intermediate layer II made of an excipient, which is then coated with an intermediate layer III containing a carbonate. In Example 45, a lag time of 3 minutes and a rapid drug release rate of 12.6% / min were both achieved. On the other hand, in Comparative Example 18, there was no lag time because there was no coating layer containing a water-soluble polymer. The masked particles of Example 45 contain zolpidem tartrate as the drug, unlike Examples 1 to 44. It can be seen that the drug release inhibition time and drug release rate can be appropriately controlled regardless of the type of drug. Furthermore, the masked particles of Example 45 differ from Examples 1 to 44 in that tartaric acid is used as the acid. It can be seen that the drug release inhibition time and drug release rate can be appropriately controlled regardless of the type of acid. In addition, the masked particles of Example 45 had a mass ratio of the masking layer to the mass of the drug-containing particles of 90%, and although the masking layer was very thick, the drug release inhibition time and drug release rate could also be appropriately controlled in this case.
[0115] The compositions of the drug-containing particles of Example 44 and Comparative Example 17 are shown in Table 6, and the compositions of the drug-containing particles of Example 45 and Comparative Example 18 are shown in Table 7. [Table 6]
[0116] [Table 7]
[0117] (13) Particle size distribution measurement Tables 8-10 show the results of measuring the particle size distribution of the masked particles of Examples 1-42, 44, and 45, and the core particles, intermediate layer-coated particles, and drug layer-coated particles of Comparative Examples 1-18. [Table 8]
[0118] [Table 9]
[0119] [Table 10] [Industrial Applicability]
[0120] The masking particles of the present invention do not release drugs in the mouth after ingestion, and even if the drug contains a drug with an unpleasant taste, the taste is not felt, and the absorption of the drug from the oral cavity and pharynx is suppressed. In addition, since the drug is released quickly after swallowing, the drug is sufficiently absorbed in the digestive tract. In addition, since the release suppression time of the drug can be arbitrarily and accurately controlled, it can be made into a suitable formulation according to the type and dosage form of the drug.
Claims
1. The masked particles (excluding tablets) are drug-containing particles that contain a drug, an acid, and a carbonate, and are coated with a coating layer containing a water-insoluble polymer, the acid being at least one selected from organic acids, organic acid salts, and hydrates thereof, the coating layer having a content of 0.01 to 2 parts by weight per part by weight of the drug-containing particle, the acid content being 3 to 35% by weight based on the total amount of the drug-containing particle, and the carbonate content being 3 to 35% by weight based on the total amount of the drug-containing particle.
2. The masked particle of claim 1 , wherein the carbonate is one or more water-soluble carbonates.
3. 3. The masking particle according to claim 1, comprising 0.1 to 10 parts by weight of carbonate per 1 part by weight of the acid.
4. The masked particle according to any one of claims 1 to 3, wherein the drug-containing particle is a uniform particle containing a drug, an acid, and a carbonate salt.
5. The masked particle according to any one of claims 1 to 3, wherein the drug-containing particle comprises a portion containing the drug and a portion containing an acid and a carbonate.
6. The masked particle described in claim 5, wherein the drug-containing particle consists of a core particle and an intermediate layer covering it, and the drug is contained in the core particle and the acid and carbonate are contained in the intermediate layer, or the acid and carbonate are contained in the core particle and the drug is contained in the intermediate layer.
7. The masked particle of claim 6 , wherein the core particle comprises a disintegrant.
8. 8. Masked particles according to claim 6 or 7, wherein the intermediate layer comprises a binder and / or a flow agent or lubricant.
9. The masked particle according to any one of claims 1 to 3, wherein the drug-containing particle has a portion containing an acid and a portion containing a carbonate separately.
10. The masked particle described in claim 9, wherein the drug-containing particle consists of a core particle and an intermediate layer covering it, the acid and the carbonate are contained separately in either the core particle or the intermediate layer, and the drug is contained in the core particle, the intermediate layer, or both.
11. The masked particle of claim 10 , wherein the core particle comprises a disintegrant.
12. 12. Masked particles according to claim 10 or 11, wherein the intermediate layer comprises a binder and / or a flow agent or lubricant.
13. The masked particle described in claim 9, wherein the drug-containing particle consists of a core particle and first and second intermediate layers, and the drug, acid, and carbonate are separately contained in either the core particle, the first intermediate layer, or the second intermediate layer.
14. The masked particle of claim 13 , wherein the core particle comprises a disintegrant.
15. 15. The masked particle according to claim 13 or 14, wherein either or both of the first and second intermediate layers comprises a binder and / or a flow agent or lubricant.
16. A tablet, granule, fine granule, or powder comprising the masked particles according to any one of claims 1 to 15.
17. An orally disintegrating tablet comprising the masked particles according to any one of claims 1 to 15.
18. A method for controlling the dissolution or release of a drug from a drug-containing particle by adding an acid and a carbonate to the drug-containing particle and coating the drug-containing particle containing the drug, acid, and carbonate with a coating layer containing a water-insoluble polymer, wherein the acid is at least one selected from organic acids, organic acid salts, and hydrates thereof, the coating amount of the coating layer is 0.01 to 2 parts by weight per part by weight of the drug-containing particle, the acid content of the drug-containing particle after the addition of the acid is 3 to 35% by weight, and the carbonate content of the drug-containing particle after the addition of the carbonate is 3 to 35% by weight (however, tablets are excluded from the particles obtained by coating drug-containing particles with a coating layer).
Citation Information
Patent Citations
Medical tablet which can release incorporated active ingredient in continuous time
JP1995138150A
Time-release particulate pharmaceutical composition for oral administration and intraorally rapidly disintegrating tablet containing said composition
JP4277904B2
Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition
WO2005105045A1
